Skip to main content

Table 2 Mean change in PET Centiloids from OLE baseline to OLE week 52 and OLE week 104 in patients with and without ≥ 1 ARIA-E event

From: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

  OLE week 52 OLE week 104
Patients with ≥ 1 ARIA-E event MR-DBP (n = 13) MR-DBA (n = 8) SR (n = 7) Total (n = 28) MR-DBP (n = 6) MR-DBA (n = 3) SR (n = 4) Total (n = 13)
 Centiloid composite ROI—mean cerebellum gray
  Baseline value, mean (SD) 90.47 (31.67) 68.01 (48.78) 67.19 (38.31) 78.23 (39.03) 82.35 (33.94) 63.94 (41.02) 78.83 (40.21) 77.02 (34.97)
  Value at visit, mean (SD) 51.38 (23.42) 11.16 (38.04) 22.21 (28.82) 32.60 (33.73) 18.22 (21.77) 11.77 (50.63) 5.18 (24.58) 12.72 (28.46)
  Change from baseline, mean (SD) − 39.09 (30.90) − 56.85 (29.52) − 44.98 (33.43) − 45.64 (30.93) − 64.13 (20.28) − 52.17 (28.66) − 73.65 (33.89) − 64.30 (25.72)
  OLE week 52 change from baseline, mean (SD) NA NA NA NA − 32.53 (31.50) − 47.26 (12.93) − 55.24 (40.53) − 42.91 (31.01)
Patients without an ARIA-E event MR-DBP (n = 14) MR-DBA (n = 13) SR (n = 12) Total (n = 39) MR-DBP (n = 10) MR-DBA (n = 8) SR (n = 8) Total (n = 26)
 Centiloid composite ROI—mean cerebellum gray
  Baseline value, mean (SD) 91.65 (58.77) 86.65 (53.87) 39.39 (58.71) 73.90 (60.36) 97.15 (68.72) 81.59 (66.35) 65.02 (42.53) 82.47 (60.19)
  Value at visit, mean (SD) 46.93 (45.38) 44.30 (45.29) 32.95 (42.31) 41.75 (43.67) 25.34 (31.63) 18.53 (40.38) 34.64 (34.31) 26.10 (34.47)
  Change from baseline, mean (SD) − 44.72 (38.26) − 42.35 (21.23) − 6.45 (53.14) − 32.15 (41.99) − 71.81 (48.25) − 63.06 (32.84) − 30.38 (17.33) − 56.37 (39.37)
  OLE week 52 change from baseline, mean (SD)b NA NA NA NA − 41.80 (38.85) − 46.72 (20.26) − 18.68 (16.79) − 36.90 (29.92)
  1. an = 11 in SR and total n = 38 at OLE week 104
  2. bn = 7 in SR and total n = 25 at OLE week 104